InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.004 -0.004 (-50%)+
Announcement
Release
31 Oct 2025 8:57AM
Price at Release
$0.008
Full Release
download
Summary
Percheron Therapeutics Limited, an international biotechnology company, announced a quarterly activities report highlighting progress with its lead program HMBD-002. Positive clinical data from a phase I trial showed a favorable safety profile and potential efficacy in cancer patients. Preclinical data for HMBD-002 demonstrated promise in treating triple-negative breast cancer and squamous cell carcinoma. The company plans to launch a multi-arm phase II clinical trial in CY2026. Financial activities included significant R&D spending and a tax incentive rebate received. Additionally, Percheron launched an interactive investor hub to enhance stakeholder engagement, closing the quarter with a cash balance of $5.68 million.
Key Points
  • Percheron Therapeutics Limited reported positive clinical data from the phase I clinical trial of HMBD-002.
  • HMBD-002 showed a favorable safety profile and potential efficacy in certain cancer patients.
  • Preclinical data for HMBD-002 was positive in triple-negative breast cancer and squamous cell carcinoma of the head and neck.
  • Percheron plans a multi-arm phase II clinical trial for HMBD-002 to start in CY2026.
  • Financial expenditures included $1.93 million for R&D and $3.07 million for investing activities.
  • The company received an R&D Tax Incentive rebate of $1.43 million.
  • Percheron launched an interactive investor hub to engage with stakeholders.
  • Cash balance at the end of the quarter was $5.68 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.